U.S. FDA staff raises efficacy doubts on GSK's lung disease treatment

U.S. Food and Drug Administration staff reviewers have raised doubts over the effectiveness of GlaxoSmithKline Plc's drug Nucala in treating a disease that limits airflow to the lungs.

from Reuters: Health https://ift.tt/2LvhrZ6
via IFTTT

• Tweet
• Share
• Share
• Share
• Share